NZ756629A - A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease - Google Patents

A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease

Info

Publication number
NZ756629A
NZ756629A NZ756629A NZ75662918A NZ756629A NZ 756629 A NZ756629 A NZ 756629A NZ 756629 A NZ756629 A NZ 756629A NZ 75662918 A NZ75662918 A NZ 75662918A NZ 756629 A NZ756629 A NZ 756629A
Authority
NZ
New Zealand
Prior art keywords
medicament
antibody
dose
administered
seq
Prior art date
Application number
NZ756629A
Other versions
NZ756629B2 (en
Inventor
Koichiro Yoneyama
Zenjiro Sampei
Kenji Shinomiya
Norihito Shibahara
Yoshinori Tsuboi
Taku Fukuzawa
Kenta Haraya
Katrijn Bogman
Jean Eric Charoin
Original Assignee
Hoffmann La Roche
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SG10201700775YA external-priority patent/SG10201700775YA/en
Priority claimed from SG10201705954VA external-priority patent/SG10201705954VA/en
Application filed by Hoffmann La Roche, Chugai Pharmaceutical Co Ltd filed Critical Hoffmann La Roche
Publication of NZ756629A publication Critical patent/NZ756629A/en
Publication of NZ756629B2 publication Critical patent/NZ756629B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)

Abstract

The present invention relates to pharmaceutical compositions for use in the treatment or prevention of a C5-related disease and methods for treating or preventing a C5-related disease. The present invention further relates to dosages and administrations of anti-C5 antibody or pharmaceutical compositions containing the anti-C5 antibody.

Claims (36)

CLAIMS ]
1. [Claim 1] Use of an anti-C5 antibody in the manufacture of a medicament for the treatment or prevention of a C5-related disease, wherein the medicament is to be administered by subcutaneous injection, and wherein the initial dose of the medicament is to be administered after a dose of another pharmaceutical composition, wherein the other pharmaceutical composition is to be administered by intravenous injection and comprises the anti-C5 antibody, wherein the anti-C5 antibody comprises a heavy chain variable domain (VH) comprising HVR-H1 comprising the amino acid sequence of SEQ ID NO: 3, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 4, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 5 and a light chain variable domain (VL) comprising HVR-L1 comprising the amino acid sequence of SEQ ID NO: 7, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 8, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 9, and wherein the C5-related disease is selected from the group consisting of rheumatoid arthritis (RA); lupus nephritis; ischemia-reperfusion injury; paroxysmal nocturnal hemoglobinuria (PNH); atypical hemolytic uremic syndrome (aHUS); dense deposit disease (DDD); macular degeneration; hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome; thrombotic thrombocytopenic purpura (TTP); spontaneous fetal loss; Pauci-immune vasculitis; epidermolysis bullosa; recurrent fetal loss; multiple sclerosis (MS); traumatic brain injury; refractory generalized myasthenia gravis (gMG); neuromyelitis optica (NMO); and injury resulting from myocardial infarction, cardiopulmonary bypass or hemodialysis.
2. [Claim 2] The use of claim 1, wherein the initial dose of the medicament for subcutaneous injection is to be administered on the same day as or 1 day to 28 days after the dose of the other pharmaceutical composition for intravenous injection.
3. [Claim 3] The use of claim 1 or claim 2, wherein the medicament for subcutaneous injection is to be given once every 3 to 42 days.
4. [Claim 4] The use of any one of claims 1 to 3, wherein the other composition for intravenous injection is to be administered once.
5. [Claim 5] The use of any one of claims 1 to 4, wherein the medicament for subcutaneous injection is to be given at a dose of 17 to 6,000 mg of the antibody.
6. [Claim 6] The use of any one of claims 1 to 5, wherein the other composition for intravenous injection is to be given at a dose of 50 to 5,000 mg of the antibody.
7. [Claim 7] The use of claim 1, wherein (a) the other pharmaceutical composition is to be administered by intravenous injection once at 500 mg, 1,000 mg, or 1,500 mg of the antibody; and (b) the medicament for subcutaneous injection is to be administered by subcutaneous injection two or more times which comprises subcutaneous injection (i) at 340 mg of the antibody once every week or once every two weeks, or (ii) at 600 mg to 2,000 mg of the antibody once every four weeks.
8. [Claim 8] The use of any one of claims 1 to 7, wherein the medicament for subcutaneous injection is for the treatment or prevention of the C5-related disease in a subject who has been treated with at least one pharmacological product for the treatment or prevention of the disease, wherein the initial dose of the other pharmaceutical composition for intravenous injection is to be administered after the final dose of the pharmacological product.
9. [Claim 9] The use of claim 8, wherein the initial dose of the other pharmaceutical composition for intravenous injection is to be administered on the third day or after 3 days after the final dose of the pharmacological product.
10. [Claim 10] The use of claim 8 or claim 9, wherein the pharmacological product comprises an siRNA targeting C5 mRNA, or an anti-C5 antibody which is different from the anti-C5 antibody comprised in the composition.
11. [Claim 11] The use of any one of claims 8 to 10, wherein the pharmacological product comprises eculizumab or its derivative.
12. [Claim 12] Use of an anti-C5 antibody in the manufacture of a medicament for the treatment or prevention of a C-5 related disease, wherein the medicament is to be administered by intravenous injection, and wherein a dose of the medicament is to be administered before the initial dose of another pharmaceutical composition, wherein the other pharmaceutical composition is to be administered by subcutaneous injection and comprises the anti-C5 antibody wherein the anti-C5 antibody comprises a heavy chain variable domain (VH) comprising HVR-H1 comprising the amino acid sequence of SEQ ID NO: 3, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 4, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 5 and a light chain variable domain (VL) comprising HVR-L1 comprising the amino acid sequence of SEQ ID NO: 7, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 8, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 9 , and wherein the C5-related disease is selected from the group consisting of rheumatoid arthritis (RA); lupus nephritis; ischemia-reperfusion injury; paroxysmal nocturnal hemoglobinuria (PNH); atypical hemolytic uremic syndrome (aHUS); dense deposit disease (DDD); macular degeneration; hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome; thrombotic thrombocytopenic purpura (TTP); spontaneous fetal loss; Pauci-immune vasculitis; epidermolysis bullosa; recurrent fetal loss; multiple sclerosis (MS); traumatic brain injury; refractory generalized myasthenia gravis (gMG); neuromyelitis optica (NMO); and injury resulting from myocardial infarction, cardiopulmonary bypass or hemodialysis.
13. [Claim 13] The use of claim 12, wherein the initial dose of the other pharmaceutical composition for subcutaneous injection is to be administered on the same day as or 1 day to 28 days after the dose of the medicament for intravenous injection.
14. [Claim 14] The use of claim 12 or claim 13, wherein the other pharmaceutical composition for subcutaneous injection is to be given once every 3 to 42 days.
15. [Claim 15] The use of any one of claims 12 to 14, wherein the medicament for intravenous injection is to be administered once.
16. [Claim 16] The use of any one of claims 12 to 15, wherein the other pharmaceutical composition for subcutaneous injection is to be given at a dose of 17 to 6,000 mg of the antibody.
17. [Claim 17] The use of any one of claims 12 to 16, wherein the medicament for intravenous injection is to be given at a dose of 50 to 5,000 mg of the antibody.
18. [Claim 18] The use of claim 12, wherein (a) the medicament for intravenous injection is to be administered by intravenous injection once at 500 mg, 1,000 mg, or 1,500 mg of the antibody; and (b) the other pharmaceutical composition is to be administered by subcutaneous injection two or more times which comprises subcutaneous injection (i) at 340 mg of the antibody once every week or once every two weeks, or (ii) at 600 mg to 2,000 mg of the antibody once every four weeks.
19. [Claim 19] The use of any one of claims 12 to 18, wherein the medicament for intravenous injection is for the treatment or prevention of the C5-related disease in a subject who has been treated with at least one pharmacological product for the treatment or prevention of the disease, wherein the initial dose of the medicament for intravenous injection is to be administered after the final dose of the pharmacological product.
20. [Claim 20] The use of claim 19, wherein the initial dose of the medicament for intravenous injection is to be administered on the third day or after 3 days after the final dose of the pharmacological product.
21. [Claim 21] The use of claim 19 or claim 20, wherein the pharmacological product comprises an siRNA targeting C5 mRNA, or an anti-C5 antibody which is different from the anti-C5 antibody comprised in the composition.
22. [Claim 22] The use of any one of claims 19 to 2, wherein the pharmacological product comprises eculizumab or its derivative.
23. [Claim 23] Use of an anti-C5 antibody in the manufacture of a medicament for the treatment or prevention of a C5-related disease, wherein the medicament is formulated to provide a dose of the medicament by subcutaneous injection and a dose of the medicament by intravenous injection, wherein the dose of the medicament by intravenous injection is to be administered before the dose of the medicament by subcutaneous injection, and wherein the anti-C5 antibody comprises a heavy chain variable domain (VH) comprising HVR-H1 comprising the amino acid sequence of SEQ ID NO: 3, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 4, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 5 and a light chain variable domain (VL) comprising HVR-L1 comprising the amino acid sequence of SEQ ID NO: 7, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 8, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 9 , and wherein the C5-related disease is selected from the group consisting of rheumatoid arthritis (RA); lupus nephritis; ischemia-reperfusion injury; paroxysmal nocturnal hemoglobinuria (PNH); atypical hemolytic uremic syndrome (aHUS); dense deposit disease (DDD); macular degeneration; hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome; thrombotic thrombocytopenic purpura (TTP); spontaneous fetal loss; Pauci-immune vasculitis; epidermolysis bullosa; recurrent fetal loss; multiple sclerosis (MS); traumatic brain injury; refractory generalized myasthenia gravis (gMG); neuromyelitis optica (NMO); and injury resulting from myocardial infarction, cardiopulmonary bypass or hemodialysis.
24. [Claim 24] The use of claim 23, wherein the dose of the medicament for subcutaneous injection is to be administered on the same day as or 1 day to 28 days after the dose of the medicament for intravenous injection.
25. [Claim 25] The use of any one of claim 23 or claim 24, wherein the medicament for subcutaneous injection is to be given once every 3 to 42 days.
26. [Claim 26] The use of any one of claims 23 to 25, wherein the medicament for intravenous injection is to be administered once.
27. [Claim 27] The use of any one of claims 23 to 26, wherein the medicament for subcutaneous injection is to be given at a dose of 17 to 6,000 mg of the antibody.
28. [Claim 28] The use of any one of claims 23 to 27, wherein the medicament for intravenous injection is to be given at a dose of 50 to 5,000 mg of the antibody.
29. [Claim 29] The use of claim 23, wherein (a) the medicament for intravenous injection is to be administered by intravenous injection once at 500 mg, 1,000 mg, or 1,500 mg of the antibody; and (b) the medicament for subcutaneous injection is to be administered by subcutaneous injection two or more times which comprises subcutaneous injection (i) at 340 mg of the antibody once every week or once every two weeks, or (ii) at 600 mg to 2,000 mg of the antibody once every four weeks.
30. [Claim 30] The use of any one of claims 23 to 29, wherein the medicament is for the treatment or prevention of the C5-related disease in a subject who has been treated with at least one pharmacological product for the treatment or prevention of the disease, wherein the initial dose of the medicament for intravenous injection is to be administered after the final dose of the pharmacological product.
31. [Claim 31] The use of claim 30, wherein the initial dose of the medicament for intravenous injection is to be administered on the third day or after 3 days after the final dose of the pharmacological product.
32. [Claim 32] The use of claim 30 or claim 31, wherein the pharmacological product comprises an siRNA targeting C5 mRNA, or an anti-C5 antibody which is different from the anti-C5 antibody comprised in the medicament.
33. [Claim 33] The use of any one of claims 30 to 32, wherein the pharmacological product comprises eculizumab or its derivative.
34. [Claim 34] The use of any one of claims 1 to 33, wherein the anti-C5 antibody comprises the heavy chain variable domain (VH) consisting of the amino acid sequence of SEQ ID NO: 2 and the light chain variable domain (VL) consisting of the amino acid sequence of SEQ ID NO: 6.
35. [Claim 35] The use of claim 34, wherein the anti-C5 antibody further comprises the CH sequence of SEQ ID NO: 13 and the CL sequence of SEQ ID NO: 18.
36. [Claim 36] The use of any one of claims 1-35 substantially as herein described and with reference to each example thereof and with reference to the figures.
NZ756629A 2018-01-31 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease NZ756629B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201700775YA SG10201700775YA (en) 2017-01-31 2017-01-31 A Pharmaceutical Composition For Use In The Treatment Or Prevention Of A C5-Related Disease And A Method For Treating Or Preventing A C5-Related Disease
SG10201705954VA SG10201705954VA (en) 2017-07-20 2017-07-20 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
PCT/JP2018/003193 WO2018143266A1 (en) 2017-01-31 2018-01-31 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease

Publications (2)

Publication Number Publication Date
NZ756629A true NZ756629A (en) 2025-09-26
NZ756629B2 NZ756629B2 (en) 2026-01-06

Family

ID=

Also Published As

Publication number Publication date
BR112019015426A2 (en) 2020-05-26
UA129282C2 (en) 2025-03-12
ES2947735T3 (en) 2023-08-17
RU2019126664A (en) 2021-03-02
US20230250162A1 (en) 2023-08-10
MX2022012931A (en) 2022-11-08
WO2018143266A1 (en) 2018-08-09
MX2019007749A (en) 2019-09-09
KR20190104982A (en) 2019-09-11
CA3051389A1 (en) 2018-08-09
JP2018141025A (en) 2018-09-13
EP4223774A3 (en) 2023-09-27
US20190367599A1 (en) 2019-12-05
CN110167961A (en) 2019-08-23
JP6383122B2 (en) 2018-08-29
PH12019501706A1 (en) 2020-03-16
JP7581292B2 (en) 2024-11-12
JP7141865B2 (en) 2022-09-26
KR20230043247A (en) 2023-03-30
EP3577135B1 (en) 2023-04-19
EP3577135A1 (en) 2019-12-11
KR20180099625A (en) 2018-09-05
EP4223774A2 (en) 2023-08-09
JP2022168209A (en) 2022-11-04
TW201922286A (en) 2019-06-16
MY201148A (en) 2024-02-07
US20200407432A1 (en) 2020-12-31
TWI658834B (en) 2019-05-11
IL268327A (en) 2019-09-26
KR102365871B1 (en) 2022-02-21
AU2018215039B2 (en) 2024-06-13
CR20220563A (en) 2022-12-07
CR20190403A (en) 2019-10-10
TWI828672B (en) 2024-01-11
IL268327B1 (en) 2025-05-01
IL307593A (en) 2023-12-01
TW201831201A (en) 2018-09-01
KR102514175B1 (en) 2023-03-29
JP2025016617A (en) 2025-02-04
JP2018123125A (en) 2018-08-09
KR101949891B1 (en) 2019-02-19
AU2024216280A1 (en) 2024-09-12
PL3577135T3 (en) 2023-12-04
TW202412841A (en) 2024-04-01
RU2019126664A3 (en) 2021-05-25
SG11201801401UA (en) 2018-09-27
SG10201908697XA (en) 2019-10-30
IL268327B2 (en) 2025-09-01
KR20220027265A (en) 2022-03-07
AU2018215039A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
JP2018141025A5 (en)
HRP20240823T1 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease
RU2017119543A (en) ANTI-TIM3 ANTIBODIES AND WAYS OF THEIR APPLICATION
FI3897672T3 (en) Combination hbv therapy
JP2020019769A5 (en)
JP2022512713A5 (en)
RU2009149462A (en) ANTIBODIES AGAINST NRR NOTCH1 AND WAYS OF THEIR APPLICATION
IL272674B2 (en) Compositions for use in treating or preventing graft-versus host disease or diffuse alveolar hemorrhage or veno-occlusive disease associated with hematopoietic stem cell transplant
AR091462A1 (en) ANTI-PCSK9 ANTIBODIES, FORMULATIONS, DOSAGE AND METHODS OF USE
HUE034465T2 (en) Monoclonal antibodies for tumor treatment
RU2016137110A (en) ANTIBODIES TO COMPONENT OF COMPLETE C5
RU2021117293A (en) ANTIBODIES AGAINST HtrA1 AND METHODS OF THEIR APPLICATION
JP2021512107A5 (en)
JP2022513350A5 (en)
JP2021510523A5 (en)
JP2023553399A5 (en)
JP2020521798A5 (en)
NZ756629B2 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
JP2017515843A5 (en)
JP2022101535A5 (en)
JP2022104920A5 (en)
RU2023101857A (en) PHARMACEUTICAL COMPOSITION INTENDED FOR USE FOR THE TREATMENT OR PREVENTION OF A C5-RELATED DISEASE, AND A METHOD OF TREATMENT OR PREVENTION OF A C5-RELATED DISEASE
RU2019126664A (en) PHARMACEUTICAL COMPOSITION FOR USE FOR TREATMENT OR PREVENTION OF C5-RELATED DISEASE AND METHOD FOR TREATMENT OR PREVENTION OF C5-RELATED DISEASE
IL316218A (en) Compositions and methods for treating ocular diseases
EP3280732B1 (en) Antibodies binding to canine vascular endothelial growth factor and uses thereof in treating canine angiogenesis-related diseases